These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 6461466

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 9. The turnover time of calcium in the exchangeable pools of bone in man and the long-term effect of a parathyroid hormone fragment.
    Reeve J.
    Clin Endocrinol (Oxf); 1978 Jun; 8(6):445-55. PubMed ID: 668151
    [Abstract] [Full Text] [Related]

  • 10. Fluoride therapy and parathyroid hormone activity in osteoporosis.
    Stamp TC, Saphier PW, Loveridge N, Kelsey CR, Goldstein AJ, Katakity M, Jenkins MV, Rose GA.
    Clin Sci (Lond); 1990 Sep; 79(3):233-8. PubMed ID: 2169371
    [Abstract] [Full Text] [Related]

  • 11. Treatment of osteoporosis with recombinant parathyroid hormone, utilisation of total body DXA to observe treatment effects on total body composition and factors determining response to therapy.
    Siddique N, Fallon N, Steen G, Walsh JB, Casey MC.
    Ir J Med Sci; 2019 May; 188(2):505-515. PubMed ID: 30032480
    [Abstract] [Full Text] [Related]

  • 12. Comparison of parathyroid hormone and strontium ranelate in combination with whole-body vibration in a rat model of osteoporosis.
    Hoffmann DB, Sehmisch S, Hofmann AM, Eimer C, Komrakova M, Saul D, Wassmann M, Stürmer KM, Tezval M.
    J Bone Miner Metab; 2017 Jan; 35(1):31-39. PubMed ID: 26825660
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy.
    de Bakker CM, Altman AR, Tseng WJ, Tribble MB, Li C, Chandra A, Qin L, Liu XS.
    Bone; 2015 Apr; 73():198-207. PubMed ID: 25554598
    [Abstract] [Full Text] [Related]

  • 15. Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT.
    Hansen S, Hauge EM, Beck Jensen JE, Brixen K.
    J Bone Miner Res; 2013 Apr; 28(4):736-45. PubMed ID: 23044908
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM.
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.